Widespread chlamydial infection in koalas results in significant morbidity and mortality and is therefore a major threat for declining population density across Australia. Antibiotics are currently one of the main therapeutic measures but the asymptomatic nature of the disease reduces their efficacy. A koala C. pecorum vaccine has been under development for the past four years .The first koala vaccine trial demonstrated the ability for rMOMP based vaccine for three different adjuvants inducing cellular and humoral immunity in female koalas and identified the immune-stimulating complex (ISC) as the best suited adjuvant for koalas. The most current koala vaccine trial formulated with a single dose vaccine regime with rMOMP adjuvanted with Poly I: C, small peptides and polyphosphazine had producing long lasting cellular and humoral immunity in koalas. Immunized koalas produced a strong Ig G response in systemic, as well as at mucosal, sites. Moreover, they showed high levels of C. pecorum specific neutralizing antibodies in the plasma as well as vaginal and conjunctival secretions. Lastly, Chlamydia specific lymphocyte proliferation responses were produced against both whole chlamydial elementary bodies and rMOMP protein for the entire study period (1 year). Therefore, a single dose rMOMP vaccine adjuvanted with poly I:C, small peptide and polyphosphazine is able to stimulate both arms of the immune system in koalas thereby providing an alternative to antibiotic treatment and/or a three-shot vaccine regime.